Showing results (211-220 of 224) with videos related to
Sort By:
Pageof 23
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 5, 2024
Measuring HIV Acquisitions Among Partners of Key Populations: Estimates From HIV Transmission Dynamic ModelsRomain Silhol, Rebecca L Anderson, Oliver Stevens, et al.Plos One|October 15, 2011
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 preventionAndrew Mujugira, Jared M Baeten, Deborah Donnell, et al.The Lancet. HIV|October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A Marzinke, Brett Hanscom, Zhe Wang, et al.Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.The Journal of Infectious Diseases|March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.Journal of the International AIDS Society|December 9, 2024
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohortBrenda Gati Mirembe, Deborah Donnell, Meighan Krows, et al.The New England Journal of Medicine|July 18, 2019
Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)Richard J Hayes, Deborah Donnell, Sian Floyd, et al.The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.Pageof 23